As political pressure on the pharmaceutical industry builds, Merck has become the latest big drug maker to commit to halting price hikes.
In a brief statement, the company agreed not to increase the average net prices of its medicines by more than inflation annually, and then also dropped the wholesale — or list — price by 60 percent on its Zepatier hepatitis C treatment and lowered list prices by 10 percent on a half dozen other drugs. However, the extent to which its moves will actually be meaningful are being questioned.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
About the Author
This is / was news to me – “And Gilead Sciences, Roche, and Novo Nordisk have begun to rescind some price hikes.” I wonder if I am alone, or if Mr. Ed was ‘making news’ very subtly.
https://www.bloomberg.com/news/articles/2018-07-10/drugmakers-cancel-price-hikes-as-california-law-takes-effect